Assessment of step-down of inhaled corticosteroids (ICS) in patients with controlled asthma

Assessment of step-down of inhaled corticosteroids (ICS) in patients with controlled asthma - Prediction of future risk in patients with controlled asthma during step-down of ICS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011565

Enrollment

400

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adults (age between 18 and 80). 2) Asthma under control during the last 3 months. (Juniper Asthma Questionnaire < 1 point). 3) Treated with a combination of ICS and long-acting beta-agonist (LABA) or ICS alone. 4) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with uncontrolled co-morbid diseases such as cardio-vascular disease, cerebral disease, renal disease, endocrine disease and gastrointestinal disease. 2) Pregnancy and woman who is lactating or if of childbearing potential. 3) Treatment with oral corticosteroids or immunosuppressant therapy. 4) Patients with seasonal exacerbations and predicted worsen of symptoms within one year. 5) Unsuitable for the study in the judgment of their attending physician.

Design outcomes

Primary

Measure	Time frame
Severe exacerbation: requiring oral steroids, emergency visits or hospitalization [Time Frame: 12 months].	—

Secondary

Measure	Time frame
Intermittent withdrawal of step-down judged by their attending physician according to worsen symptoms [Time Frame: 12 months].	—

Countries

Japan

Contacts

Public ContactAkira Yamasaki

Tottori University Faculty of Medicine Department of Third Internal Medicine, Respiration/Collagen and Vascular Disease

yamasaki@grape.med.tottori-u.ac.jp+81-859-38-6537

Outcome results